Johnson & Johnson vs Neurocrine Biosciences Inc
JNJ vs NBIX — side-by-side comparison from reported financials. JNJ leads 5, NBIX leads 4 of 9 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Neurocrine Biosciences Inc
NBIX · Healthcare
$142.44+0.84%Strong
| Metric | JNJ | NBIX |
|---|---|---|
| Price | $261.79 | $142.44 |
| Market cap | $631B | $14.5B |
| Revenue (TTM) | $97.9B | $3.37B |
| Revenue growth | +5.6% | +24.3% |
| Net margin | 21.5% | 20.9% |
| Free cash flow | $22.2B | $866M |
| Net cash (debt) | ($27.8B) | $1.01B |
| 1-year price return | +37.0% | +2.9% |
| P/E | 29.9 | 20.5 |
| P/E vs own history (cheap-side %) | 16% | 90% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | 21% |
| Altman Z-score | — | 6.23 |
| CV checks passed | 10 of 11 | 10 of 11 |
| Employees | 140,800 | 2,500 |
Full résumé-style profiles: JNJ CV · NBIX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.